Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
711 (USA) · Dr. Jansen
consented 2013-01-27
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate ASTHENIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-05 (study day 10.0); relationship: REMOTE
mild
assessed
Mild HYPERTENSION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-07-23 (study day -188.0); relationship: NONE
moderate
assessed
Moderate HYPERTENSION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-07-23 (study day -188.0); relationship: NONE
Data queries
No data queries.